Lefamulin Acetate

CHEMBL3545309 Phase 4 Одобрено Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
567.8 g/mol
LogP
Phase
4

A acetate salt form of lefamulin with the same therapeutic properties. This pleuromutilin antibiotic treats community-acquired bacterial pneumonia with activity against multidrug-resistant pathogens.

Молекулярная масса

567,8000 g/mol

TPSA

172,00 Ų

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D Структура

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

C=C[C@]1(C)C[C@@H](OC(=O)CS[C@@H]2CC[C@@H](N)C[C@H]2O)[C@]2(C)[C@H](C)CC[C@]3(CCC(=O)[C@H]32)[C@@H](C)[C@@H]1O.CC(=O)O

InChI

InChI=1S/C28H45NO5S.C2H4O2/c1-6-26(4)14-22(34-23(32)15-35-21-8-7-18(29)13-20(21)31)27(5)16(2)9-11-28(17(3)25(26)33)12-10-19(30)24(27)28;1-2(3)4/h6,16-18,20-22,24-25,31,33H,1,7-15,29H2,2-5H3;1H3,(H,3,4)/t16-,17+,18-,20-,21-,22-,24+,25+,26-,27+,28+;/m1./s1

Molecular Formula

C30H49NO7S

HBD / HBA

4 / 9

Вращаемые Связи

6

Тяжёлые Атомы

39

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Часто задаваемые вопросы

A acetate salt form of lefamulin with the same therapeutic properties. This pleuromutilin antibiotic treats community-acquired bacterial pneumonia with activity against multidrug-resistant pathogens.

Yes, Lefamulin Acetate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL3545309. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 86346053. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Медицинский отказ от ответственности

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.